IN2014DN03429A - - Google Patents

Info

Publication number
IN2014DN03429A
IN2014DN03429A IN3429DEN2014A IN2014DN03429A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A IN 3429DEN2014 A IN3429DEN2014 A IN 3429DEN2014A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A
Authority
IN
India
Prior art keywords
inhibitor
matrix
allergene
whereon
adsorbed
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Grunwald
WEBER Carsten B SCHMIDT
Original Assignee
Pls Design Gmbh
Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pls Design Gmbh, Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh filed Critical Pls Design Gmbh
Publication of IN2014DN03429A publication Critical patent/IN2014DN03429A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3429DEN2014 2011-11-23 2012-11-23 IN2014DN03429A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11075261.5A EP2596802A1 (en) 2011-11-23 2011-11-23 Pharmaceutical composition for treatment of allergic reactions
PCT/EP2012/004884 WO2013075846A1 (en) 2011-11-23 2012-11-23 Pharmaceutical composition for treatment of allergic reactions

Publications (1)

Publication Number Publication Date
IN2014DN03429A true IN2014DN03429A (ko) 2015-06-05

Family

ID=47358079

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3429DEN2014 IN2014DN03429A (ko) 2011-11-23 2012-11-23

Country Status (6)

Country Link
US (2) US20140335162A1 (ko)
EP (1) EP2596802A1 (ko)
CN (1) CN104039349A (ko)
BR (1) BR112014012277A2 (ko)
IN (1) IN2014DN03429A (ko)
WO (1) WO2013075846A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
SG11201705064XA (en) * 2014-12-24 2017-07-28 Neximmune Inc Nanoparticle compositions and methods for immunotherapy
CN105727371B (zh) * 2016-01-25 2019-04-09 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料
CN107669638B (zh) * 2017-10-23 2020-05-22 华南理工大学 一种peg-pcl-peg三嵌段共聚物修饰的羟基积雪草苷脂质体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4137333A1 (de) 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
JP2000515007A (ja) 1996-06-14 2000-11-14 バイエル・コーポレーシヨン Ｔ細胞選択的インターロイキン―４アゴニスト
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
ES2239408T3 (es) 1997-10-03 2005-09-16 Macromed Inc. Copolimeros tribloque de poli(lactido-co-glicolido) polietilenglicol de bajo peso molecular biodegradables con propiedades de gelificacion termica inversa.
BR9908466A (pt) * 1998-03-02 2000-12-05 Applied Vaccine Technologies C Proceso para modular a resposta imune, em um mamìfero, a um antìgeno, dispositivo inplantável para modular uma resposta imune a um antìgeno, e, processos para obter células imunes de um mamìfero, para imunização de um mamìfero com um antìgeno, para a produção de hibridomas produzindo anticorpos monoclonais humanos contra um antìgeno pré-selecionado, para transfectar células imunes de um mamìfero com material genético, e para o tratamento ou profilaxia de uma doença ou condição causada por uma resposta imune
ID26963A (id) * 1998-03-02 2001-02-22 Applied Vaccine Technologies C Metoda dan alat untuk memodulasi respon kekebalan
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
AU2001273413A1 (en) 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
EP1785490B1 (en) 2005-10-17 2007-11-14 RiNA Netzwerk RNA-Technologien GmbH Method for determining an unknown PNA sequence and uses thereof
EP1984015A4 (en) * 2006-01-11 2011-11-30 Aerovance Inc METHOD AND COMPOSITIONS FOR TREATING ASTHMA IN HUMANS AND OTHER PRIMATES
US10736848B2 (en) * 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
TWI468191B (zh) * 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
JP5656370B2 (ja) 2009-07-01 2015-01-21 キヤノン株式会社 画像処理装置、画像処理システム、画像処理方法、およびプログラム

Also Published As

Publication number Publication date
BR112014012277A2 (pt) 2019-09-24
EP2596802A1 (en) 2013-05-29
US20180117143A1 (en) 2018-05-03
WO2013075846A1 (en) 2013-05-30
CN104039349A (zh) 2014-09-10
US20140335162A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
EP3354640A3 (en) Mif inhibitors and their uses
MX2012003185A (es) Composiciones farmaceuticas que comprenden bi-1356 y metformina.
MX341025B (es) Terapia de combinacion.
PL2600865T3 (pl) Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
UY33937A (es) Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
MX345777B (es) Formulaciones de tabletas bicapa.
IN2012DN02805A (ko)
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112015011430A2 (pt) composição para liberação imediata e prolongada
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
IN2014DN03429A (ko)
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.